Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases.
Neutral protease activity was significantly elevated in the cerebro-spinal fluid of patients with multiple sclerosis (MS) in exacerbation and in the acute phase of acute viral meningoencephalitis (AME) compared with that of MS in remission, amyotrophic lateral sclerosis or psychosomatic disease. Since in each relapse of MS, protease activity was higher in exacerbation than in remission, this activity may be one good marker of disease activity in MS. One hundred micro molar of FOY305, synthetic protease inhibitor, inhibited in vitro increased neutral protease activity in MS in exacerbation, which suggests the possibility of a clinical application of this protease inhibitor for MS.
Inuzuka
T
T
Sato
S
S
Baba
H
H
Miyatake
T
T
D000690:Amyotrophic Lateral Sclerosis / Q000201:enzymology; D010450:Endopeptidases / Q000134:cerebrospinal fluid*; D004952:Esters; D005500:Follow-Up Studies; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008590:Meningoencephalitis / Q000201:enzymology; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000201:enzymology*; D015260:Neprilysin; D009422:Nervous System Diseases / Q000201:enzymology*; D011480:Protease Inhibitors / Q000627:therapeutic use; D011602:Psychophysiologic Disorders / Q000201:enzymology
D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D016670:Gabexate; D010450:Endopeptidases; D015260:Neprilysin